Business Wire

Positive Results of EfficAPSI Real-World Study Confirm Significant Benefit of Sublingual Liquid AIT Treatment on the Onset and Worsening of Asthma in Patients With Allergic Rhinitis


Stallergenes Greer, a global healthcare company specialising in allergen immunotherapy (AIT), today announced positive data from its EfficAPSI real-world study. Presented at the 2022 European Academy of Allergy and Clinical Immunology (EAACI) congress in Prague (Czech Republic), the real-world study confirmed significant benefit of sublingual liquid allergen immunotherapy treatment (AIT) on the onset and worsening of asthma in patients with allergic rhinitis.

The retrospective longitudinal pharmaco-epidemiological real-world study included over 430,000 patients: more than 100,000 patients with allergic rhinitis with or without asthma treated with sublingual liquid immunotherapy and symptomatic drugs; compared to more than 330,000 patients with allergic rhinitis with or without asthma treated with symptomatic drugs only.

The primary objective of the study was the evaluation of the impact of sublingual liquid AIT on the onset and worsening of asthma in patients with allergic rhinitis. Study results were consistent across all age groups (patients above age of 5), allergens and endpoints, and showed:

  • a reduction of the risk of asthma onset of more than 20% observed in patients undergoing treatment with sublingual liquid AIT and symptomatic drugs versus patients treated with symptomatic drugs only;
  • a reduction of the risk of asthma worsening of 28% and reaching 37% for severe forms.

The results of the EfficAPSI real-world study confirm and broaden the findings of randomised clinical trials and strengthen the body of evidence of the positive impact of sublingualliquidAIT on the onset and worsening of allergic asthma in patients with allergic rhinitis. They highlight the relevance of etiological treatment while further demonstrating the efficacy of AIT on patients with allergies,” said Professor Pascal Demoly, MD, PhD, HDR, Head of the Pulmonology, Allergology and Thoracic Oncology Department, Montpellier University Hospital (France) and member of the study’s scientific committee.

“Large, robust real-world datasets, which allow us to assess additional aspects of AIT treatment, are critical to improving care for patients with allergies. Stallergenes Greer initiated and contributed to the development of real-world evidence in the field of allergy; these data allow us to deepen our knowledge and understanding of patient outcomes in real life, while providing substantial information on increasingly common allergens. This landmark study further demonstrates the positive impact of Stallergenes Greer’s sublingual allergen immunotherapy treatments on public health,” declared Michele Antonelli, Chief Executive Officer, Stallergenes Greer.

Analysis of the results regarding the secondary objective of the EfficAPSI study is underway.


EfficAPSI is the largest retrospective real-world, longitudinal cohort study regarding sublingual liquid allergen immunotherapy treatment. Its objective is to evaluate the real life impact of sublingual liquid allergen immunotherapy on the onset and worsening of asthma in patients with allergic rhinitis. This study included more than 100,000 patients in France with allergic rhinitis with or without asthma treated with sublingual liquid AIT and symptomatic drugs and more than 330,000 patients with allergic rhinitis with or without asthma treated with symptomatic drugs only.

EfficAPSI is the first study in the AIT field in which the French national system database (SNDS), covering 99% of the French population, has been used to gain insight on therapeutic benefits in real life practice by pairing their data with the data of a healthcare company.

Onset or worsening of asthma were defined as the first occurrence of a specific pharmacy dispensation, hospital discharge summaries or long-term diseases or asthma in the main analysis; pharmacy dispensation was omitted for a more specific, secondary definition, focusing on severe forms of asthma. Analyses were stratified on pre-existing mild or moderate asthma to differentiate between the onset and worsening of asthma.

A total of 101,345 exposed (sublingual liquid AIT) and 333,082 unexposed patients (control) were included.

Onset of asthma data: among allergic rhinitis patients without pre-existing asthma, sublingual liquid AIT was associated with a significantly lower risk of occurrence of asthma when compared to control group (symptomatic drugs only), according to main (HR: 0.78, 95% CI 0.77-0.79) and secondary definition (HR: 0.80, 95% CI 0.73-0.87).

Worsening of asthma data: among allergic rhinitis patients with pre-existing asthma, sublingual liquid AIT was associated with a significantly lower risk of worsening of asthma when compared to control group (symptomatic drugs only), according to main (HR: 0.72, 95% CI 0.71-0.73) and secondary definition (HR: 0.63, 95% CI 0.59-0.66).

The EfficAPSI study covers a wide range of allergens including house dust mites, grass, birch, ragweed pollens, and cat. Results are positive and consistent for all allergens and all age groups.

The study was designed with a scientific committee composed by Prof. Pascal Demoly, MD, PhD, HDR, Head of the Pulmonology, Allergology and Thoracic Oncology Department, Montpellier University Hospital (France); Prof. Philippe Devillier, Hôpital Foch, Paris (France); Dr. Jean François Bergman, Head of Internal Medicine, Hôpital Lariboisière, Paris, Professor of Therapeutics, Paris-Diderot University (France). Dr. Bertrand Delaisi, Paris (France), and Dr. Mathieu Molimard, Bordeaux (France).


Allergic rhinitis is a worldwide disease affecting more than 500 million people, who are at higher risk of developing rhinitis exacerbation and asthma than the general population. Allergic rhinitis can include symptoms such as sneezing, a runny or itchy nose, nasal congestion and watery or itchy eyes, among othersi, ii. Symptoms may be severe and can worsen over time and have a significant impact on quality of life1, iii, iv, v, vi.


Headquartered in Baar (Switzerland), Stallergenes Greer International AG is a global healthcare company specialising in the diagnosis and treatment of allergies through the development and commercialisation of allergen immunotherapy products and services. Stallergenes Greer International AG is the parent company of Greer Laboratories, Inc. (whose registered office is in the United States) and Stallergenes SAS (whose registered office is in France). For more information, visit

i Demoly P, Corren J, Creticos P, et al. A 300 IR sublingual tablet is an effective, safe treatment for house dust mite–induced allergic rhinitis: An international, double-blind, placebo- controlled, randomized phase III clinical trial. J Allergy Clin Immunol. 2021
ii Bousquet J, Khaltaev N, Cruz A, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008 Apr;63 Suppl 86:8-160.
iii Brozek JL, Bousquet J, Agache I, Agarwal A, Bachert C, Bosnic-Anticevich S, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines— 2016 revision. J Allergy Clin Immunol. 2017;140(4):950–8
iv Linneberg A., Henrik Nielsen N., Frolund L, et al. The link between allergic rhinitis and allergic asthma: a prospective population-based study. The Copenhagen Allergy Study. Allergy. 2002 Nov;57(11):1048-1052.
v Shin J-W, Sue J-H, Song T-W, et al. Atopy and house dust mite sensitization as risk factors for asthma in children. Yonsei Med J.2005;46: 629- 634.
vi Hankin C. S., Cox L., Lang D.,et al. Allergen immunotherapy and health care cost benefits for children with allergic rhinitis: a large-scale, retrospective, matched cohort study. Ann Allergy Asthma Immunol. 2010 Jan;104(1):79-85

To view this piece of content from, please give your consent at the top of this page.

Contact information

Stallergenes Greer
Catherine Kress
+33 (0)1 55 50 26 05

About Business Wire

Business Wire
Business Wire

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Abionic Receives IVDR Certification for Its Predictive Ultra-Rapid Sepsis Test Allowing the Management of Antibiotic Administration9.8.2022 06:00:00 CEST | Press release

Abionic SA, a developer of disruptive nanotechnology-based diagnostic solutions, has announced that its Pancreatic Stone Protein (PSP) test on the abioSCOPE® has been certified by BSI certification agency as complying with the European In-vitro Diagnostic Regulation (IVDR), EU 2017/746. This certification granted by notified bodies like BSI is required for in-vitro diagnostics to continue being sold in the European Union. The IVDR’s extensive requirements were adopted by the European Parliament in 2017 and must now be implemented by May 26, 2022. This press release features multimedia. View the full release here: FIVE MINUTES TO SAVE LIVES - Immediate clinical decision-making at your fingertips (Photo: Business Wire) IVDR becomes mandatory as of May 26, 2022. There are also transitional rules that will allow well-established instruments that have not been IVDR certified, but that entered the EU before, to still be sold until 202

A Digital Twin of Kabuki Actor Shido Nakamura Created with NTT’s Another Me Technology Debuts at “Cho Kabuki 2022 Powered by NTT”9.8.2022 05:03:00 CEST | Press release

NTT Corporation (President: Akira Shimada, “NTT”) and Shochiku Co., Ltd. (President & CEO: Junichi Sakamoto) have announced "Cho Kabuki 2022 Powered by NTT" sponsored by Shochiku, with the first act starring Shido Nakamura's digital twin, “Shido Twin.” The debut of Shido Twin showcases NTT’s research and development of a computer that reproduces people as digital twins and is the first step in the social implementation of this new technology. We hope you will come and witness the birth of Shido Nakamura reproduced as a digital twin. Created in collaboration with Shochiku Co., Ltd., the Shido Twin autonomously reproduces the gestures of Shido Nakamura, who plays the leading role in Cho-kabuki, using the body motion generation technology of Another Me. Another Me is a technology born out of NTT’s Digital Twin Computing1 concept. With Another Me, we aim to allow individuals to create an “alternative self” in the digital space, dramatically increasing the opportunities to flourish and grow

IFF Reports Second Quarter 2022 Results8.8.2022 22:21:00 CEST | Press release

International Flavors & Fragrances Inc. (NYSE: IFF) reported financial results for the second quarter ended June 30, 2022. Management Commentary "We continued to execute on our near-term operational priorities to achieve strong top and bottom-line results in the second quarter," said IFF CEO Frank Clyburn. "Our teams have acted with urgency to implement necessary pricing actions in collaboration with our customers and delivered productivity benefits that offset on-going inflationary pressures. Going forward, we are preparing for more uncertain market conditions, yet remain confident in delivering our full year financial objectives. At the same time, we are advancing our strategic efforts, deploying innovation, refining our portfolio and strengthening our culture to deliver strong value creation for all our stakeholders. Reflecting our confidence, we are pleased to announce that we are raising our quarterly dividend. This marks thirteen years of consecutive dividend increases and unders

Waldom Electronics Announces New Advisory Board8.8.2022 20:30:00 CEST | Press release

Waldom Electronics is excited to announce the launch of its Advisory Board comprised of recognized leaders who will bring their knowledge and experience to the company. The Advisory Board will work closely with Don Akery, Waldom’s Chief Executive Officer, to help maximize performance with special focus on long term strategy. This press release features multimedia. View the full release here: Kevin Rock (Photo: Business Wire) Waldom’s Chairman, Jamil Nizam stated, “In order to build on our significant growth over the last several years, I have been working diligently to create a world-class Advisory Board. I am thrilled to have assembled this board of exceptional individuals who will bring their skills, experience and objectivity to help Waldom realize its goals, vision and mission.” Waldom welcomes the following members to its Advisory Board: - Kevin Rock, Former President of TE Connectivity’s Industrial Solutions Segment with o

Sermo Barometer Reveals Growing Concern Among Global Physicians Regarding Monkeypox8.8.2022 16:00:00 CEST | Press release

With the spread of monkeypox on the rise and the World Health Organization (WHO) declaring a global health emergency, findings from a recent survey conducted by Sermo, a physician-first online community and leader in global HCP insights, show there is high concern about public misinformation spreading. The survey also found that while 71% of respondents would recommend vaccination as a preventative measure to a patient who was concerned about contracting monkeypox, 65% of doctors say their country does not have enough vaccines. The barometer survey included 1,011 physician respondents from 20 countries, with key findings including: Concerns About Misinformation Seventy-eight percent of physician respondents are concerned about the spread of monkeypox misinformation and 60% are concerned that monkeypox is being categorized incorrectly as a sexually transmitted disease, such as syphilis or HPV. Based on lessons from the COVID-19 pandemic, 36% feel public health authorities should priorit

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom